Malignant Thoracic Neoplasm

72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated … (full text at CIViC)

PMID 25668009 · Walter et al., 2015 · Open in CIViC

72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated … (full text at CIViC)

PMID 25668009 · Walter et al., 2015 · Open in CIViC

In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations received the MET inhibitor Capmatinib after assignment to cohorts based on prior treatment and type of M… (full text at CIViC)

PMID 32877583 · Wolf et al., 2020 · Open in CIViC

In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib. MET amplification was defined as MET/CEP7 ration >… (full text at CIViC)

PMID 31416808 · Landi et al., 2019 · Open in CIViC

A 74-year-old woman with stage II Pulmonary Sarcomatoid Carcinoma (PSC) was treated with neoadjuvant platinum/taxane chemotherapy with no improvement. Chemotherapy was stopped due to resistance and po… (full text at CIViC)

PMID 26215952 · Liu et al., 2016 · Open in CIViC

A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation or MET amplification. Univariable analysis showed that shorter overall disease-specific survival was … (full text at CIViC)

PMID 26847053 · Tong et al., 2016 · Open in CIViC

A 76-year old male (non-smoker) presented with stage IV lung adenocarcinoma with metastatic disease in the lung and thoracic vertebra (T2). Next-generation sequencing revealed a MET exon 14 skipping m… (full text at CIViC)

PMID 27257131 · Liu et al., 2016 · Open in CIViC

64-year old female (non-smoker) was diagnosed with NSCLC. A c.3028 G->A mutation was identified in exon 14 resulting in exon 14 skipping. Further, amplification of the MET gene was observed. The patie… (full text at CIViC)

PMID 26729443 · Awad et al., 2016 · Open in CIViC

An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

A patient diagnosed with lung adenocarcinoma had cells cultured to create patient-derived cell lines. Such cells exhibited MET amplification and showed overexpression of MYC. Capmatinib was administer… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

Lung adenocarcinoma cell lines (H3122: EML4-ALK E13:A20, HCC78: SLC34A2-ROS1, H1993: MET amplification, and H596: MET exon 14 skipping) with putative crizotinib-sensitive genotypes were analyzed with … (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

This study contained 230 patients presenting with untreated lung adenocarcinoma. Tumor and matched normal material were analyzed via whole-exome sequencing. It was shown that ~62% of samples contained… (full text at CIViC)

PMID 25079552 · 2014, Nature · Open in CIViC

69 patients with lung adenocarcinoma from Beth Israel Deaconess Medical Center had their cancers submitted for genomic profiling to identify crizotinib-sensitive genomic events. There were 7 cases tha… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

Case Report of a a 56-year-old female (never-smoker) patient with stage IV NSCLC. NGS revealed a MET–ATXN7L1 fusion. No additional known driver gene alterations were identified. Following progression … (full text at CIViC)

PMID 30339198 · Zhu et al., 2018 · Open in CIViC

In a lung adenocarcinoma patient harboring MET D1028H mutation, a partial response to crizotinib treatment was reported with continued response for at least 6 months. Prior to crizotinib treatment, th… (full text at CIViC)

PMID 25898962 · Waqar et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring a MET D1010H mutation, stable disease to crizotinib monotherapy was reported. The patient was treated with crizotinib for 4 months; treatment was ongoing at … (full text at CIViC)

PMID 27343443 · Schrock et al., 2016 · Open in CIViC

A female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial resp… (full text at CIViC)

PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC

In a lung adenocarcinoma patient with a MET D1010_splice mutation, a partial response to crizotinib treatment was reported with a 45.1% decrease in tumor measurement by RECIST v1.1. The patient experi… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing… (full text at CIViC)

PMID 27343443 · Schrock et al., 2016 · Open in CIViC

Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.

PMID 27343442 · Heist et al., 2016 · Open in CIViC

Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC)

PMID 27694386 · Bahcall et al., 2016 · Open in CIViC

Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC)

PMID 27694386 · Bahcall et al., 2016 · Open in CIViC

In a phase 2 trial, patients with NSCLC harboring MET alterations were treated with crizotinib. MET alterations were kinase domain activating mutations included V1110L, H1112L, H1112Y, H1124D, M1149T,… (full text at CIViC)

PMID 31932802 · Drilon et al., 2020 · Open in CIViC

In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib. MET amplification was defined as MET/CEP7 ration >… (full text at CIViC)

PMID 31416808 · Landi et al., 2019 · Open in CIViC

A 33-year old male patient (non-smoker) was diagnosed with Stage IVB adenosquamous lung carcinoma. Various treatment strategies were tried but all had progressive disease quickly after treatment. Next… (full text at CIViC)

PMID 33854337 · Jiao et al., 2021 · Open in CIViC

A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC)

PMID 30762593 · Wang et al., 2019 · Open in CIViC